hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06289998, orgStudyIdInfo id: RP014-01, briefTitle: Study of Tamibarotene in Patients With ADPKD, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-22, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Rege Nephro Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease, conditionsModule conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD), designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Tamibarotene, interventions name: Placebo, outcomesModule primaryOutcomes measure: Changes in TKV from baseline, secondaryOutcomes measure: Changes in TLV from baseline, secondaryOutcomes measure: Changes in eGFR from baseline, secondaryOutcomes measure: Incidence of adverse events, eligibilityModule sex: ALL, minimumAge: 26 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Kurume University Hospital, status: RECRUITING, city: Kurume, state: Fukuoka, zip: 830-0011, country: Japan, geoPoint lat: 33.31667, lon: 130.51667, locations facility: Hokkaido University Hospital, status: RECRUITING, city: Sapporo, state: Hokkaido, zip: 060-8648, country: Japan, geoPoint lat: 43.06667, lon: 141.35, locations facility: Shonan Kamakura General Hospital, status: RECRUITING, city: Kamakura, state: Kanagawa, zip: 247-8533, country: Japan, geoPoint lat: 35.30889, lon: 139.55028, locations facility: Toranomon Hospital Kajigaya, status: RECRUITING, city: Kawasaki, state: Kanagawa, zip: 213-8587, country: Japan, geoPoint lat: 35.52056, lon: 139.71722, locations facility: Juntendo University School of Medicine Juntendo Hospital, status: RECRUITING, city: Bunkyo-ku, state: Tokyo, zip: 113-8431, country: Japan, geoPoint lat: 35.37517, lon: 139.92991, locations facility: Toranomon Hospital, status: RECRUITING, city: Minato-ku, state: Tokyo, zip: 105-8470, country: Japan, geoPoint lat: 34.2152, lon: 135.1501, locations facility: Tokyo Women's Medical University Hospital, status: RECRUITING, city: Shinjukuku, state: Tokyo, zip: 162-8666, country: Japan, geoPoint lat: 35.2946, lon: 139.57059, locations facility: Kyoto University Hospital, status: RECRUITING, city: Kyoto, zip: 606-8507, country: Japan, geoPoint lat: 35.02107, lon: 135.75385, hasResults: False
protocolSection identificationModule nctId: NCT06289985, orgStudyIdInfo id: STEP, secondaryIdInfos id: 1OT2NS129366-01, type: NIH, link: https://reporter.nih.gov/quickSearch/1OT2NS129366-01, briefTitle: StrokeNet Thrombectomy Endovascular Platform, acronym: STEP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2028-06, completionDateStruct date: 2028-09, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Medical University of South Carolina, class: OTHER, collaborators name: National Institute of Neurological Disorders and Stroke (NINDS), collaborators name: University of Cincinnati, collaborators name: University of Virginia, collaborators name: Berry Consultants, collaborators name: University of California, Los Angeles, collaborators name: MOUNT SINAI HOSPITAL, collaborators name: The Cooper Health System, collaborators name: University of Pittsburgh Medical Center, collaborators name: Stony Brook University, collaborators name: University at Buffalo, descriptionModule briefSummary: STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO)., conditionsModule conditions: Ischemic Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: FACTORIAL, interventionModelDescription: Adaptive Bayesian Platform Trial evaluating multiple interventions in multiple domains., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 2000, type: ESTIMATED, armsInterventionsModule interventions name: Endovascular thrombectomy with any FDA-approved category POL or NRY device, interventions name: Medical Management, outcomesModule primaryOutcomes measure: Global disability measured by Modified Rankin Score, otherOutcomes measure: Global disability measured by Modified Rankin Score, otherOutcomes measure: Neurological deficit as measured by the National Institutes of Health Stroke Scale (NIHSS), otherOutcomes measure: Symptomatic intracranial hemorrhage, otherOutcomes measure: Any radiologic intracranial hemorrhage, otherOutcomes measure: Mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06289972, orgStudyIdInfo id: HUvbayraktaroglu1, briefTitle: Development,Validity and Reliability of a Caregiver Version of the Breathlessness Beliefs Questionnaire, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-20, primaryCompletionDateStruct date: 2025-02-20, completionDateStruct date: 2025-02-20, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Halic University, class: OTHER, descriptionModule briefSummary: The goal of this methodological study is to determine the reliability and validity of the The Breathlessness Beliefs Questionnaire Caregiver Version (BBQ-C) version in assessing dysfunctional breathlessness beliefs in caregivers of children with cystic fibrosis., conditionsModule conditions: Cystic Fibrosis, conditions: Parents, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 22, type: ESTIMATED, outcomesModule primaryOutcomes measure: The Breathlessness Beliefs Questionnaire (Caregiver Version) (BBQ-C), secondaryOutcomes measure: Cystic Fibrosis Questionnaire Revised (CFQ-R) for parent version, secondaryOutcomes measure: Parent Attitude Scale (PAS), secondaryOutcomes measure: Perceived Social Support Scale (PSS), secondaryOutcomes measure: Parent Attitude Scale, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Haliç University, status: RECRUITING, city: Istanbul, state: Eyup, zip: 34060, country: Turkey, contacts name: Vildan Bayraktaroglu, PT, MSc, role: CONTACT, phone: (0212) 924 24 44, email: vildanbayraktaroglu@halic.edu.tr, contacts name: Seda Saka, PT, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06289959, orgStudyIdInfo id: JD-LC2023006-I01, briefTitle: Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-25, primaryCompletionDateStruct date: 2029-01-01, completionDateStruct date: 2029-01-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Second Affiliated Hospital of Soochow University, class: OTHER, descriptionModule briefSummary: A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and treatment practices for DLBCL patients., conditionsModule conditions: Lymphoma, Large B-Cell, Diffuse, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: cfDNA, outcomesModule primaryOutcomes measure: Progression-free survival（PFS）, secondaryOutcomes measure: Sensitivity, and specificity of plasma cfDNA in DLBCL patients, secondaryOutcomes measure: Overall survivals(OS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Second Affiliated Hospital of Soochow University, city: Suzhou, state: Jiangsu, zip: 215000, country: China, contacts name: Bingzong Li, Professor, role: CONTACT, phone: 0086-13776054037, email: lbzwz0907@hotmail.com, geoPoint lat: 31.30408, lon: 120.59538, hasResults: False
protocolSection identificationModule nctId: NCT06289946, orgStudyIdInfo id: NitroRadialLHC, briefTitle: Topical Nitro or Placebo Pre-Cath, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Thomas Jefferson University, class: OTHER, descriptionModule briefSummary: Phase 2, single-center, randomized, blinded clinical study to assess the safety and efficacy of topical nitroglycerin on ease of TRA during scheduled PCI. We will compare topical nitroglycerin to placebo applied prior to planned, non-urgent PCI to determine if nitroglycerin is associated with decreased number of arterial puncture attempts made, decreased time to radial access, and lower crossover rate to TFA. Subjects will be randomized to receive either topical nitroglycerin ointment or placebo prior to scheduled PCI. There will be 256 subjects enrolled in this study with 1:1 randomization., conditionsModule conditions: Coronary Artery Disease, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 256, type: ESTIMATED, armsInterventionsModule interventions name: NitroBid, interventions name: Placebo, outcomesModule primaryOutcomes measure: Crossover rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06289933, orgStudyIdInfo id: BR-EMC-CT-103, briefTitle: A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fed Conditions in Healthy Adult Volunteers, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-03, completionDateStruct date: 2024-03, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Boryung Pharmaceutical Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The objective of this clinical study is to compare the pharmacokinetics and the safety between a fixed-dose combination administration of "BR3005" and co-administration of "BR3005-1" and "BR3005-2" under fed conditions in healthy adult volunteers, conditionsModule conditions: Type2 Diabetes Mellitus, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: BR3005, interventions name: BR3005-1, interventions name: BR3005-2, outcomesModule primaryOutcomes measure: AUCτ, primaryOutcomes measure: Cmax, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Clinical Research Center, H PLUS Yangji Hospital, status: RECRUITING, city: Seoul, state: Gwanakgu, zip: 08779, country: Korea, Republic of, contacts name: Seunghyun Kang, role: CONTACT, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06289920, orgStudyIdInfo id: BR-EMC-CT-102, briefTitle: A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult Volunteers, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-03, completionDateStruct date: 2024-03, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Boryung Pharmaceutical Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The objective of this clinical study is to compare the pharmacokinetics and the safety between a fixed-dose combination administration of "BR3005" and co-administration of "BR3005-1" and "BR3005-2" under fasting conditions in healthy adult volunteers, conditionsModule conditions: Type 2 Diabetes Mellitus, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: BR3005, interventions name: BR3005-1, interventions name: BR3005-2, outcomesModule primaryOutcomes measure: AUCτ, primaryOutcomes measure: Cmax, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Clinical Research Center, H PLUS Yangji Hospital, status: RECRUITING, city: Seoul, state: Gwanakgu, zip: 08779, country: Korea, Republic of, contacts name: Seunghyun Kang, role: CONTACT, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06289907, orgStudyIdInfo id: LH-BH-ADV-01, briefTitle: Hot Flash and Night Sweat Virtual Study, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-07-09, primaryCompletionDateStruct date: 2024-05-30, completionDateStruct date: 2024-07-30, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Bonafide Health, class: INDUSTRY, collaborators name: Lindus Health, descriptionModule briefSummary: The purpose of this research study is to evaluate the effectiveness of the study product on vasomotor symptoms (VMS) and overall menopause symptoms in healthy women, who are perimenopausal or postmenopausal, and aged 40 - 65., conditionsModule conditions: Menopause, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Decentralized, double-blind, placebo-controlled, randomized, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: Double-blind, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Bonafide-HF3.0, interventions name: Placebo, outcomesModule primaryOutcomes measure: To determine the effects of the Study Product (SP) compared to placebo on hot flash symptoms, primaryOutcomes measure: To determine the effects of the SP compared to placebo on hot flash symptoms, primaryOutcomes measure: To determine the effects of the SP compared to placebo on hot flash symptoms, primaryOutcomes measure: To determine the effects of the SP compared to placebo on vasomotor symptoms, primaryOutcomes measure: To determine the effects of the SP compared to placebo on overall menopausal symptoms, primaryOutcomes measure: To determine the effects of the SP compared to placebo on overall menopausal symptoms, primaryOutcomes measure: To determine the effects of the SP compared to placebo on quality of life, eligibilityModule sex: FEMALE, minimumAge: 40 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Lindus Health, Inc., city: London, country: United Kingdom, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06289894, orgStudyIdInfo id: BRY805-101, briefTitle: A Study of BRY805 in Participants With Advanced Solid Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2027-05, completionDateStruct date: 2027-09, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: BioRay Pharmaceutical Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This is a phase 1 open label multicenter study to evaluate safety, tolerance and the maximum tolerance of BRY805 administered intravenously (IV) once every three weeks in participants with advanced solid tumors, so as to confirm the recommended phase 2 dose of BRY805 and obtain the preliminary efficacy information of participants with advanced solid tumors., conditionsModule conditions: Advanced Solid Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: BRY805 injection, outcomesModule primaryOutcomes measure: Occurrence of Drug Limited Toxicities (DLTs), primaryOutcomes measure: Type and incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs), secondaryOutcomes measure: BRY805 Serum Concentrations, secondaryOutcomes measure: Number of Participants with BRY805 Antibodies, secondaryOutcomes measure: Overall Response Rate (ORR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Progression-Free Survival (PFS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shandong Tumor hospital, city: Jinan, state: Shandong, zip: 250117, country: China, contacts name: Jinming Yu, MD, role: CONTACT, phone: (+86)0531-67627156, email: sdyujinming@126.com, geoPoint lat: 36.66833, lon: 116.99722, hasResults: False
protocolSection identificationModule nctId: NCT06289881, orgStudyIdInfo id: SIL-026-21, briefTitle: Sildenafil 100 mg Tablets Relative to Viagra 100 mg Tablets, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-02-04, primaryCompletionDateStruct date: 2025-03-11, completionDateStruct date: 2025-03-25, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Bio-innova Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 3 days washout period between the doses., conditionsModule conditions: Healthy Subjects, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Sildenafill-Test product, interventions name: Sildenafill-Reference product, outcomesModule primaryOutcomes measure: Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t), primaryOutcomes measure: Maximal measured plasma concentration (Cmax), secondaryOutcomes measure: Number of subjects with adverse events, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06289868, orgStudyIdInfo id: DC-TR23-0222, secondaryIdInfos id: HAV-EU-11-23, type: OTHER, domain: Beckman Coulter, Inc, briefTitle: Access Anti-HAV and Access Anti-HAV IgM Assays EU Clinical Trial Protocol (HAV-EU-11-23), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-27, primaryCompletionDateStruct date: 2024-05-27, completionDateStruct date: 2024-08-27, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Beckman Coulter, Inc., class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate the clinical performance supporting that intended purpose of the Access anti-HAV as an aid in the laboratory diagnosis of HAV infection and for detection of anti-HAV after vaccination and of the Access anti-HAV IgM assay as an aid in the laboratory diagnosis of acute or recent HAV infection, on the DxI 9000 Access Immunoassay Analyzer.This study will be used to obtain CE mark for both Access anti-HAV and anti- HAV IgM assays., conditionsModule conditions: HAV, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: OTHER, enrollmentInfo count: 1150, type: ESTIMATED, armsInterventionsModule interventions name: Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays, interventions name: Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays, outcomesModule primaryOutcomes measure: Access Anti-HAV diagnostic accuracy measured as sensitivity and specificity, primaryOutcomes measure: Access Anti-HAV IgM diagnostic accuracy measured as sensitivity and specificity, eligibilityModule sex: ALL, minimumAge: 2 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cerba Xpert, city: Frepillon, zip: 95740, country: France, contacts name: Chloé Puisney, PhD, role: CONTACT, phone: 06.30.15.34.65, email: cpuisney@cerbaresearch.com, geoPoint lat: 49.05216, lon: 2.20528, locations facility: Eurofins Biomnis, city: Ivry-sur-Seine, zip: 94208, country: France, contacts name: Catherine Coignard, MD, role: CONTACT, phone: +33 149 59 63 37, email: catherine.coignard@biomnis.eurofinseu.com, geoPoint lat: 48.81568, lon: 2.38487, hasResults: False